Neupogen and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Neupogen (filgrastim), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Weakness when taking Neupogen. It is created by eHealthMe based on reports of 23,793 people who have side effects when taking Neupogen from the FDA, and is updated regularly.

What is Neupogen?

Neupogen has active ingredients of filgrastim. It is often used in agranulocytosis. eHealthMe is studying from 23,898 Neupogen users. Check the latest studies of Neupogen.

What is Weakness?

Weakness is found to be associated with 3,639 drugs and 6,596 conditions by eHealthMe. Check the latest studies of Weakness.

On May, 01, 2026

23,793 people reported to have side effects when taking Neupogen.
Among them, 1,218 people (5.12%) have Weakness.

Among these 1,218 people:

* Approximation only. Some reports may have incomplete information.

Do you take Neupogen and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neupogen:

Neupogen (23,898 reports)

Weakness treatments and more:

Weakness (586,873 reports)

How severe was Weakness and when was it recovered:

Weakness in Neupogen

Expand to all the drugs that have ingredients of filgrastim:

Weakness and drugs with ingredients of filgrastim (1,852 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neupogen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,639 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,596 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on filgrastim (the active ingredients of Neupogen) and Neupogen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.